Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience
Makaleler > Tam Makale · 2018
Yazarlar: Ayse UYSAL, Nur AKAD SOYER, Melda Ozkan, Fahri ŞAHİN, Filiz VURAL, Mahmut TÖBÜ, Murat TOMBULOĞLU, Güray SAYDAM
TURKISH JOURNAL OF MEDICAL SCIENCES, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2018, cilt 48, ss 80-83
DOI: 10.3906/sag-1611-97
Özet
Background/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone.